

Formulary Changes Update

The following changes to the MPC Approved Drug List (ADL) were approved by the Maryland Physicians Care Pharmacy & Therapeutics Committee. Please review these changes.

Key		
UPPER CASE = Brand Name Drugs	Lower case = Generic Drugs	QL = Quantity Limit
PA = Prior Authorizations	ST = Step Therapy	AL = Age Limit
ADL = Approved Drug List	YOA = Years of Age	DD = Discontinued Drug

January 2021

No Changes

February 2021

No Changes

March 2021

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
ADAKVEO (crizanlizumab)	<i>Hematology</i>	Added to formulary; with PA	March 2021	N/A
SEVENFACT (coagulation factor VIIa)	<i>Hemostatics</i>	Added to formulary; with PA	March 2021	N/A
ZTLIDO 1.8% (lidocaine)	<i>Topical Anesthetics</i>	Added to formulary; No PA	March 2021	N/A

April 2021

No Changes

May 2021

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
GILENYA	<i>Neurologic Agent</i>	Removed from formulary	May 2021	AUBAGIO

(fingolimod)				
BREO ELLIPTA (fluticasone furoate- vilanterol)	<i>Pulmonary anti- inflammatory/Beta-Agonist combo</i>	Removed from formulary	May 2021	Fluticasone-salmeterol
TRULANCE (plecanatide)	<i>Gastrointestinal agent</i>	Removed from formulary	May 2021	AMITIZA
AMITIZA (lubiprostone)	<i>Gastrointestinal agent</i>	Added to formulary; No PA	May 2021	N/A
SPIRIVA (tiotropium bromide)	<i>Inhaled Long-Acting Muscarinic Antagonist</i>	Removed from formulary	May 2021	INCRUSE ELLIPTA
SPIRIVA RESPIMAT (tiotropium bromide)	<i>Inhaled Long-Acting Muscarinic Antagonist</i>	Removed from formulary	May 2021	INCRUSE ELLIPTA
June 2021				
No Changes				
July 2021				
No Changes				